ABSTRACT:Human carbonyl reductase 1 (CBR1) metabolizes endogenous and xenobiotic substrates such as the fever mediator, prostaglandin E2 (PGE 2 ), and the anticancer anthracycline drug, daunorubicin. We screened 33 CBR1 full-length cDNA samples from white and black liver donors and performed database analyses to identify genetic determinants of CBR1 activity. We pinpointed a single nucleotide polymorphism on CBR1 (CBR1 V88I) that encodes for a valine-toisoleucine substitution for further characterization. Human carbonyl reductase 1 (CBR1) is a monomeric cytosolic enzyme that catalyzes the two-electron reduction of biologically and pharmacologically active substrates by using NADPH as cofactor . For example, CBR1 converts the potent fever mediator prostaglandin E 2 (PGE 2 ) into the less active metabolite PGF 2␣ . Recent studies have shown that the transcription of CBR1 in lung and liver is down-regulated to suppress the catabolism of PGE 2 during the course of the febrile response (Ivanov et al., 2003;Ivanov and Romanovsky, 2004). CBR1 also plays a predominant role in the metabolism of the anticancer anthracyclines doxorubicin and daunorubicin by catalyzing the formation of their corresponding C-13 alcohol metabolites (doxorubicinol and daunorubicinol). Anthracycline C-13 alcohol metabolites circulate in plasma, have half-lives similar to those of the parent compounds, and are devoid of significant tumor cell-killing activity. The use of anthracyclines for cancer treatment is hampered by the development of clinical cardiotoxicity in some patients (Wouters et al., 2005). The pathogenesis of anthracycline-related cardiotoxicity is complex and appears to be mediated by a combination of oxidative stress and intracardiac metabolic perturbations induced by C-13 anthracycline alcohol metabolites (Minotti et al., 2004). In human myocardium, cytosolic carbonyl reductases (CBRs), and aldo/keto reductases catalyze the two-electron reduction of the anthracycline side chain C-13 carbonyl group to form cardiotoxic alcohol metabolites (e.g., doxorubicinol, daunorubicinol). CBR activity is the main source of quinone detoxification in humans, and biochemical studies showed that aldo/keto reductases have 7-to 18-fold lower catalytic efficiencies (V max /K m ) for the reduction of anthracycline substrates than CBRs (Wermuth et al., 1986;Ohara et al., 1995;Rosemond and Walsh, 2004;Covarrubias et al., 2006). The key role of CBR1 during the pathogenesis of anthracycline-related cardiotoxicity has been established in biochemical studies and in experiments with murine models (Mordente et al., 2001). Mice overexpressing human CBR1 in heart showed high intracardiac levels of doxorubicinol and increased signs of myocardial damage after doxorubicin administration . Conversely, mice with a